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Abstract
The pathogenesis of rheumatoid arthritis is poorly understood; however, ele-
vated oxidative stress has been described to be involved. In this chapter, we present 
experiments with endogenous molecules bearing antioxidative properties. In our 
studies, we used male Lewis rats, and the arthritis was induced with Mycobacterium 
butyricum. In the first experiment, we tested coenzyme Q 10 (CoQ  10) in the oral 
daily dose of 100 mg/kg b.w. Markers of inflammation and total antioxidant status 
were corrected in the group supplemented. CoQ 10 treatment significantly improved 
concentrations of the investigated endogenous antioxidants. Further as an impor-
tant fact, we consider a good bioavailability of used CoQ 10 formulation which was 
confirmed by increased CoQ concentrations in plasma, tissue, and mitochondria 
from skeletal muscles. In the second study, we describe the results with hyaluronic 
acid (HA) administered in oral daily doses of 0.5 mg and 5 mg/kg b.w. and of 
different molecular weights (0.43, 0.99, and 1.73 MDa). A notable antioxidative 
effect of HA was assessed: its administration increased the activities of antioxidant 
enzymes (superoxide dismutase and glutathione peroxidase) in erythrocytes and 
total antioxidant capacity of plasma and reduced the marker of oxidative damage 
to lipids—plasmatic lipid hydroperoxides. HA with the highest molecular weight 
showed the most significant effect.
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1. Introduction
1.1 Involvement of oxidative stress in rheumatoid arthritis
Rheumatoid arthritis (RA) is the most common inflammatory rheumatic 
disease, affecting almost 1–2% of the world’s population. Most of patients pres-
ent rheumatoid factors, which are autoantibodies directed to the Fc fraction of 
immunoglobulin G and antibodies reacting with citrullinated peptides [1, 2]. The 
pathogenesis of RA is understood incompletely. Until now, there is a lack of opti-
mal therapy against this disease. The disease is characterized by immunological 
dysfunction and chronic inflammation which results in synovial joint deformity 
and destruction. In the course of RA, the synovial membrane of diarthrodial 
joints is inflamed, and articular tissue is damaged which leads to severe functional 
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disarrangement of the entire joint. The initial stages of RA synovitis are character-
ized by proliferation of the microvasculature and secondary edema. Eventually, this 
process matures into a progressive infiltration of immune cells, including B cells, 
T cells, and monocytes from the bloodstream. These immune cells are activated in 
the joint and differentiate and acquire mature phenotypes. The influx of immune 
cells is also associated with phenotypic changes in synoviocytes, the typical resident 
cells. Both fibroblast- and monocyte-derived synoviocytes proliferate extensively 
and participate in inflammatory process. Synovial proliferation, neovasculariza-
tion, and leukocyte extravasation transform the normal synovium into an invasive 
tumor-like “pannus.” The architecture of the microvasculature is highly dysregu-
lated, and thus efficiency of oxygen supply to the synovium is poor [3]. This, along-
side with increased metabolic turnover of the expanding synovial pannus, leads to 
oxidative stress (OS), altered cellular bioenergetics, and a hypoxic microenviron-
ment, which further promotes synovial invasiveness and abnormal cell function 
within the joint [4]. Free radicals such as reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) have distinct contribution to the destructive, proliferative 
synovitis of RA and play a prominent role in cell-signaling events (Figure 1).
However, few studies had clarified the role of free radicals in the etiopatho-
genesis of RA. Significant higher serum levels of ROS and RNS in RA patients in 
comparison with healthy subjects were described. Furthermore, strong positive 
correlation between ROS, RNS, and the clinical and biochemical markers of RA was 
observed [5]. In another study glycated, oxidized, and nitrated proteins and amino 
acids were detected in synovial fluid (SF) and plasma of arthritic patients with 
characteristic patterns found in early and advanced RA, with respect to healthy 
control [6]. Combination of estimates of oxidized, nitrated, and glycated amino 
acids with hydroxyproline and anti-cyclic citrullinated peptide antibody status in 
plasma provided a biochemical test of relatively high sensitivity and specificity for 
early-stage diagnosis and typing of arthritic disease. Advanced oxidation protein 
products (AOPPs) have been confirmed to accumulate in RA patients. A study of 
Ye et al. [7] demonstrated that AOPPs induce apoptosis of human chondrocyte 
via ROS-related mitochondrial dysfunction and endoplasmic reticulum stress 
pathways. These data implicate that AOPPs may represent a novel pathogenic factor 
that contributes to RA progression. Further it seems that an accurate redox balance 
is necessary to sustain an immune state that both prevents the development of 
overt autoimmunity and minimizes collateral tissue damage [8]. The inflamed joint 
Figure 1. 
Pathological changes in arthritic joint induced by oxidative stress.
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is profoundly hypoxic, with evidence of oxidative damage and impaired mito-
chondrial dysfunction, as a result of abnormal angiogenesis and increased energy 
demands of the expanding synovial pannus [9]. In this hypoxic-inflammatory 
microenvironment, synovial cells adapt in order to survive through altering their 
cellular metabolism, which activates complex cross talk of key signaling pathways 
in the inflamed joint which further exacerbates inflammation. Thus, understand-
ing the underlying mechanisms mediating hypoxia-induced pathways, OS, and 
subsequent cellular inflammation may provide a basis for novel therapies. It is 
well documented that ROS can activate different signaling pathways having a vital 
importance in the pathophysiology of RA [10].
Our chapter is focused on two main aims:
1. To verify the hypothesis that per oral supplementation of CoQ 10 could affect 
inflammation in arthritic rats by regulating endogenous antioxidants and OS 
with detailed analysis performed in plasma and skeletal muscles.
2. To verify the hypothesis that hyaluronan per oral administration can restore 
the redox balance under the conditions of experimental arthritis. OS has been 
monitored in erythrocytes and in plasma. The effect of three different molecu-
lar weights of polysaccharides has been evaluated.
1.2  Role of antioxidant systems and endogenous antioxidants in remission of 
rheumatoid arthritis
Epidemiological studies have shown that RA occurs in previously healthy sub-
jects who had low levels of circulating antioxidants [11], implying a pathogenic role 
of increased OS in the development of RA. Patients with RA have been reported to 
have lower serum levels of a variety of antioxidants, including vitamin E, vitamin 
C, β-carotene, selenium, and zinc, in comparison with healthy individuals [12]. In 
order to prevent the damaging effect of prooxidants, the body has an antioxidant 
defense system that protects cellular systems from oxidative damage [13]. Some 
common enzymes that are involved in the neutralization of free radicals are endo-
genous enzymatic antioxidants such as superoxide dismutase (SOD), glutathione 
peroxidase (GPx), catalase (CAT), glutathione reductase (GR), and peroxiredoxins. 
These enzymes neutralize hydrogen peroxide, yielding water (CAT, GPx) and oxy-
gen (CAT) molecules. The nonenzymatic endogenous antioxidants taking part in 
the first line of defense belong to preventive antioxidants, and in blood plasma they 
are represented by metal-binding proteins as ceruloplasmin, ferritin, lactoferrin, 
transferrin, and albumin. These proteins inhibit the formation of ROS by binding 
with transition metal ions (e.g., iron and copper). Also, metallothionein plays an 
essential role in the prevention against ROS. The second line of defense against 
ROS involves nonenzymatic antioxidants that are represented by molecules chara-
cterized by the ability to rapidly inactivate radicals and oxidants. The third line 
of defense consists of repair mechanisms against damage caused by free radicals. 
This form of protection is provided by enzymatic antioxidants, which can repair 
damaged DNA and proteins, fight against oxidized lipids, stop chain propagation 
of peroxyl lipid radicals, and repair damaged cell membranes and molecules [14]. 
Dietary antioxidants (vitamins C and E, carotenoids, polyphenols, and biogenic 
elements) can affect the activity of endogenous antioxidants. Endo- and exogenous 
antioxidants may act synergistically to maintain or re-establish redox homeostasis. 
The major endogenous nonenzymatic low-molecular-mass antioxidants include 
glutathione, uric acid, melatonin, coenzyme Q , bilirubin, and polyamines. 
Considering the mechanism of antioxidant protection, the endogenous substances 
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can be divided into true scavengers, metal-buffering proteins, and chelators of 
redox-stable metals [13]. This chapter is focused on evaluating coenzyme Q10 and 
hyaluronan of different molecular weight in experimental arthritis induced in rats.
2.  Coenzyme Q10 supplementation and its contribution to therapy of 
arthritis
2.1 The protective properties of coenzyme Q
Chronic inflammation, systemic OS, and mitochondrial dysfunction are the 
main factors which participate in etiopathogenesis of arthritis. Mitochondria play a 
central role in ATP formation in the respiratory chain (Figure 2) and in maintain-
ing redox homeostasis. OS processes are activated under pathological conditions. 
Oxidative damage of mitochondria may lead to the dysfunction of the respiratory 
chain which further increases ROS formation. Thus, mitochondrial dysfunction can 
contribute to the development of inflammatory human diseases [16].
The therapy of RA is an actual problem in clinical rheumatology due to the 
toxicity and side effects of antirheumatic drugs; therefore, new treatment options 
are being sought. Methotrexate (MTX), used in the treatment of RA, can induce 
hepatocellular injury. In combination with coenzyme Q 10, anti-arthritic effect of 
MTX was potentiated, and hepatotoxicity was suppressed [17]. Preservation of 
mitochondrial function could reduce OS and may represent a novel therapeutic 
approach in patients with inflammatory diseases. Progressive muscle atrophy and 
inflammatory myopathy in RA have been proposed to be mediated by disturbances 
of myofibrils and mitochondria [18]. Due to the unique properties, coenzyme 
Q 10 (CoQ 10) can serve as a useful adjuvant in the management of arthritis. CoQ 10 
Figure 2. 
Function of coenzyme Q in mitochondrial respiratory chain. With permission of [15].
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is irreplaceable in mitochondrial bioenergetics; it participates as a cofactor of 
dehydrogenases in the transport of electrons and protons as well as in ATP produc-
tion [19]. The respiratory chain located in the inner mitochondrial membrane is 
organized into five complexes (I, II, III, IV, and V). The transport of electrons from 
NADH and FADH2 and production of electrochemical potential and proton gradi-
ents are necessary for the synthesis of ATP [20, 21]. Electrons are carried out from 
complexes I and II to complex III by coenzyme Q (CoQ ). It has been demonstrated 
that lipoperoxidation is accompanied by reduced mitochondrial CoQ concentra-
tions concomitantly with the decreased activities of respiratory chain enzymes, 
such as NADH- and succinate oxidases [22–24]. Increased levels of antioxidants 
have also been reported including CoQ in tissues as well as activities of antioxidant 
enzymes in experimental models of diseases associated with increased free radicals’ 
generation such as diabetes mellitus [25–27]. The term “redox signaling” has been 
introduced to describe a regulatory process in which protective responses against 
oxidative damage are induced to reset the oxidant-antioxidant balance [28]. CoQ 
(ubiquinone) is the only lipophilic antioxidant to be biosynthesized; the main form 
in humans is CoQ 10, in rats’ coenzyme Q 9 (CoQ 9) (Figure 3).
CoQ exerts its antioxidant function either directly on superoxide radicals or 
indirectly on lipid radicals, both singly and in cooperation with vitamin E [29]. 
Beneficial antioxidant and anti-inflammatory properties of CoQ 10 were proved in 
RA patients [30]. Tocopherols are the subgroup of vitamin E, occurring in isomers 
α, β, γ, and δ. All tocopherols are potent antioxidants with lipoperoxyl radical-
scavenging activities [31]. The main forms of tocopherols in humans are alpha-
tocopherol (αT) and gamma-tocopherol (γT) (Figure 4).
The most significant difference in metabolism of αT and γT is preferential 
binding of αT by α-TTP (α-tocopherol transfer protein). The γT is metabolized 
mainly through cytochrome P450, and formed hydrophilic metabolites are excreted 
in urine [32]. Isoforms of vitamin E differentially regulate inflammation [33]. In 
contrast to αT, γT reacts with nitrogen radicals which are formed extensively in 
inflammatory diseases such as RA. Vitamin E has a potential role in skeletal muscle 
health, in regulation of OS and inflammation [34]. Low levels of vitamin E and 
Figure 3. 
Chemical structure of coenzyme Q.
Figure 4. 
Chemical structure of tocopherols. α-tocopherol: R1 = CH3; R2 = CH3; γ-tocopherol: R1 = H; R2 = CH3.
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other endogenous antioxidants have been considered as a risk factor for the devel-
opment of RA [35]. We hypothesized that administration of CoQ 10 could affect 
inflammation in arthritic rats by regulating the endogenous antioxidants and OS.
2.2  Experimental design of adjuvant arthritis with administration  
of coenzyme Q 10
Adjuvant arthritis (AA) was induced by intradermal injection of Mycobacterium 
butyricum in incomplete Freund’s adjuvant to male Lewis rats [36, 37]. The experi-
ment included healthy control animals (HC), arthritic animals (AA), and arthritic 
animals with administration of CoQ 10 (liquid liposomal CoQ 10—LiQSorb
®) in 
the oral daily dose of 100 mg/kg b.w. (AA-CoQ ) by the use of gavage. The analyses 
were performed 28 days after the arthritis induction and in the beginning of CoQ 10 
supplementation. Concentrations of CoQ 9, CoQ 10, αT, and γT were determined by 
HPLC method with spectrophotometric detection at 275 nm (CoQ ) and 295 nm 
(tocopherols), using external standards [38, 39]. Total CoQ 9 and CoQ 10 (oxidized 
and reduced forms) in plasma was measured after oxidation with 1,4-benzoquinone 
[40]. Mitochondria from hind paw skeletal muscle tissue were isolated by means 
of differential centrifugation according to slightly modified methods [41, 42]. 
Mitochondrial proteins were estimated spectrophotometrically [43]. Data were 
collected and processed using CSW 32 chromatographic station (DataApex Ltd). 
Concentrations were calculated: in the plasma in μmol/l, in the tissue in nmol/g 
of wet weight, and in the mitochondria in nmol/mg of proteins. Total antioxidant 
status (TAS) in plasma was determined using the Randox Total Antioxidant Status 
kit with colorimetric detection at 600 nm. Markers of inflammation, C-reactive 
protein (CRP), and monocyte chemotactic protein-1 (MCP-1) were measured by 
ELISA. Data are expressed as mean ± SEM. Statistical significance between experi-
mental groups was evaluated using Student’s t-test, p < 0.05, which was considered 
as a significant result.
2.3  Evaluation of results of administration of coenzyme Q 10 in experimental 
arthritis
AA for a period of 28 days significantly increased markers of inflammation—CRP 
and MCP-1—and decreased TAS (Table 1). Concentrations of total CoQ 9 (oxidized 
and reduced) and γT in plasma of AA rats increased significantly (Table 2).
In skeletal muscle tissue and mitochondria of AA rats, concentrations of oxidized 
form of coenzyme Q 9 (CoQ 9-OX) and αT decreased significantly and CoQ 10-OX only 
slightly. Tissue γT increased compared to controls; in mitochondria the increase was 
marginally significant (p = 0.077), (Tables 3 and 4). Treatment of arthritic rats 
with CoQ 10 (AA-CoQ) for 28 days partially suppressed inflammatory markers and 
increased TAS, but not statistically significant (Table 1). Elevated concentrations 
of total CoQ 9 and γT in plasma were corrected to control values. Concentration 
of CoQ 10 in plasma increased extremely, demonstrating a good bioavailability of 
CoQ 10 administered (Table 2). In tissue and mitochondria, concentrations of CoQ 9 
and CoQ 10 increased in comparison with AA rats and were comparable to controls. 
Concentrations of αT in tissue and mitochondria also increased, in the tissue at the 
limit of significance (p = 0.071) and in mitochondria without statistical significance 
(Tables 3 and 4).
Bioenergetic and antioxidant properties of CoQ 10 are sufficiently described 
[44]. However, new research findings suggest that CoQ 10 supplementation has 
also lowering effects on circulating inflammatory mediators, including CRP, 
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interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α). Meta-analysis of clini-
cal randomized controlled trials evaluated the effects of CoQ 10 in some inflam-
matory diseases but with inconsistent results due to heterogeneity and limited 
number of studies [45].
In an experimental study, an antiarthritic effect of CoQ 10 against induced gouty 
arthritis in rats was found [46]. CoQ 10 treatment at the dosage 10 mg/kg/body  
weight for 3 days reduced paw edema, minimized lysosomal enzyme release, 
boosted antioxidant system, and suppressed lipid peroxidation. Protective mecha-
nism of CoQ 10 against cartilage degeneration induced by interleukin-1β was studied 
on isolated rat chondrocytes [47]. The study demonstrated the anticatabolic and 
cartilage protective potentials of CoQ 10 by inhibition of overexpression of matrix 
Plasma CRP MCP-1 TAS
μg/ml pg/ml mmol/l
HC 457.4 ± 21.3 1462 ± 159.2 0.673 ± 0.037
AA 602.2 ± 10.7** 2925 ± 389.1** 0.529 ± 0028*
AA-CoQ 563.3 ± 14.5 2539 ± 144.1 0.562 ± 0.033
*p < 0.05.
**p < 0.01 vs. HC.
Table 1. 
Markers of inflammation: C-reactive protein (CRP), monocyte chemotactic protein (MCP-1),  
and total antioxidant status (TAS) in plasma.
Plasma CoQ 9-TOT CoQ 10-TOT αT γT
μmol/l μmol/l μmol/l μmol/l
HC 0.328 ± 0.023 0.031 ± 0.004 19.9 ± 1.13 0.643 ± 0.051
AA 0.468 ± 0.044** 0.027 ± 0.003 21.6 ± 0.72 0.834 ± 0.060*
AA-CoQ 0.237 ± 0.016++ 0.804 ± 0.069++ 19.6 ± 1.07 0.678 ± 0.043+
*p < 0.05.
**p < 0.01 vs. HC.
+p < 0.05.
++p < 0.01 vs. AA.
Table 2. 
Concentrations of total coenzyme Q 9 (CoQ 9-TOT), total coenzyme Q10 (CoQ 10-TOT), α-tocopherol (αT),  
and γ-tocopherol (γT) in plasma.
Tissue CoQ 9-ox CoQ  10-ox αT γT
nmol/g ww nmol/g ww nmol/g ww nmol/g ww
HC 43.1 ± 3.01 1.90 ± 0.160 23.0 ± 1.23 0.98 ± 0.042
AA 32.7 ± 2.49* 1.63 ± 0.187 18.7 ± 0.829* 1.39 ± 0.155*
AA-CoQ 40.9 ± 4.07 2.43 ± 2.52+ 22.2 ± 1.42 1.07 ± 0.084
*p < 0.05 vs. HC.
+p < 0.05 vs. AA.
Table 3. 
Concentrations of oxidized forms of coenzyme Q 9 (CoQ 9-OX), coenzyme Q 10 (CoQ 10-OX), α-tocopherol (αT),  
and γ-tocopherol (γT) in the skeletal muscle tissue.
Antioxidants
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metalloproteinases which may represent a new approach in the treatment of 
patients with osteoarthritis. Administration of CoQ 10 in the dose 100 mg/kg for 
28 days suppressed cartilage degeneration by inhibiting inflammatory mediators 
and OS in an experimental model of rat osteoarthritis [48]. Beneficial effects of 
CoQ 10 supplementation on inflammatory cytokines and OS in RA patients were 
proved. In the double-blind, randomized controlled clinical trial in patients with 
RA, CoQ 10 supplementation with 100 mg/day for 2 months led to a significant 
decrease of malondialdehyde (MDA) formation and a nonsignificant increase of 
total antioxidant capacity, indicating beneficial effects on OS. CoQ 10 also sup-
pressed overexpression of inflammatory cytokines TNF-α significantly and IL-6 
nonsignificantly [30].
Our results show that administration of CoQ  10 to rats with induced adjuvant 
arthritis in the oral daily dose of 100 mg/kg b.w. for 28 days partially corrected 
inflammatory markers and TAS but without statistical significance (Table 1). 
CoQ 10 treatment corrected concentration of CoQ 9 in plasma to control value 
(Table 2). In the skeletal muscle tissue and isolated mitochondria, concen-
trations of CoQ 9 and CoQ 10 increased in comparison with AA rats and were 
comparable to controls. Concentrations of αT in tissue and mitochondria were 
also improved, in the tissue marginally significant and in mitochondria without 
statistical significance (Tables 3 and 4). Sufficient concentrations of CoQ 
together with αT, the main form of vitamin E, may be important in skeletal 
muscle function, in regulation of OS and inflammation. The role of vitamin 
E in regulation of diseases has been extensively studied in humans, animal 
models, and cell systems. It has been reported that isoforms of vitamin E may 
have opposing regulatory functions during inflammation, when supplementa-
tion with αT was anti-inflammatory and γT pro-inflammatory [33]. Different 
effects of vitamin E isoforms may result from differences in their metabolism, 
as αT is preferentially bound α-TTP (α-tocopherol transfer protein), while γT is 
metabolized mainly through cytochrome P450 and its concentrations in plasma 
and tissues are dependent on cytochrome P450 metabolism in the liver [49]. Our 
results show elevated concentrations of γT in plasma and skeletal muscle tissue 
of arthritic rats together with increased markers of inflammation and decreased 
TAS (Tables 1–3). This confirms the previous findings that inflammation and 
inhibition of the cytochrome P450 can increase γT concentration [50]. Treatment 
of arthritic animals with CoQ 10 corrected elevated levels of γT to control values 
and showed beneficial effect on concentrations of αT, CoQ 9, and CoQ 10 in the 
skeletal muscle tissue and mitochondria. This can help improve bioenergetic 
function of the skeletal muscle that is impaired by arthritic inflammatory 
Mitochondria CoQ  9-ox CoQ  10-ox αT γT
nmol/mg prt nmol/mg prt nmol/mg prt nmol/mg prt
HC 3.28 ± 0.14 0.144 ± 0.01 0.305 ± 0.02 0.042 ± 0.01
AA 2.67 ± 0.13** 0.126 ± 0.01 0.216 ± 0.02* 0.058 ± 0.01
AA-CoQ 3.16 ± 0.08++ 0.149 ± 0.01+ 0.289 ± 0.03 0.052 ± 0.01
*p < 0.05.
**p < 0.01 vs. HC.
+p < 0.05.
++p < 0.01 vs. AA.
Table 4. 
Concentrations of oxidized forms of coenzyme Q 9 (CoQ 9-OX), coenzyme Q10 (CoQ  10-OX), α-tocopherol (αT),  
and γ-tocopherol (γT) in skeletal muscle mitochondria.
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process. Elevated concentrations of endogenous antioxidants can contribute to 
regulation of oxidative stress.
3.  Hyaluronan in arthritis: regulation of inflammation through 
antioxidative effects
3.1 The protective properties of hyaluronan
OS is important in the pathogenesis of autoimmune diseases such as RA and in 
its experimental model-adjuvant arthritis. The control of inflammation and OS in 
arthritic patients by hyaluronic acid (HA) is one of the approaches to the treatment 
of RA, concentration of which is reduced in the synovial fluid of patients suffering 
from arthritis. The most important aspect from a treatment perspective is the fact 
that HA has been found to be safe and well tolerable. The widespread use of HA 
also leads to lower use of nonsteroidal anti-inflammatory drugs, which may be an 
advantage for patients. HA is a high-molecular-weight, ubiquitous glycosamino-
glycan (GAG) that naturally occurs within the cartilage and synovial fluid [51]. It is 
an anionic linear polysaccharide composed of alternating N-acetyl D-glucosamine 
and D-glucuronic acid residues attached by β(1-4) and β(1-3) glycosidic bonds 
(Figure 5) with molecular mass ranging from 6.5 to 10.9 MDa [52]. It is structurally 
the simplest compound among GAGs. HA has hydrophilic groups which not only 
form hydrogen bonds with each other but also interact with water molecules.
In physiological solutions hyaluronan manifests very unusual rheological 
properties and has exceedingly lubricious and very hydrophilic properties. This 
is the reason why HA occurs in the salt form, hyaluronate, and is present in every 
connective tissue and organ such as the skin, synovial fluid, blood vessels, serum, 
brain, cartilage, heart valves, and the umbilical cord. Synovial fluid in particular 
has the highest concentration of HA (3–4 mg/ml) compared to anywhere else in the 
body [53]. HA plays important physiological roles in living organisms which makes 
it an attractive biomaterial for various medical applications [54, 55]. HA has several 
diverse physiological functions. Because of its hygroscopic properties, hyaluronan 
significantly influences hydration and the physical properties of the extracellular 
matrix. In addition to its function as a passive structural molecule, hyaluronan also 
acts as a signaling molecule by interacting with cell surface receptors resulting in 
the activation and modulation of signaling cascades that influence inflammatory 
processes, including the antioxidant scavenging of the ROS and/or RNS arising 
from polymorphonuclear nucleosides’ respiratory bursts as well as cell migration, 
Figure 5. 
Chemical structure of hyaluronan.
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Figure 6. 
Biological effects of hyaluronan oligosaccharides depend on their molecular weight.
proliferation, and gene expression [55]. Moreover, there is a brisk metabolism of HA 
in humans, with approximately one-third (around 5 g) of total HA were degraded 
and replaced daily predominantly by the reticuloendothelial system [56].  
Many physiological effects of HA may be functions of its molecular weight. Already 
in the year 2000, Camenisch and McDonald [57] published an overview of the 
effects of HA, dependent on its molecular weight. HA of an average mass of 0.2 MDa 
prolonged survival of peripheral blood eosinophils in vitro but HA of the mass of 
3–6 MDa had a much lower effect. This observation follows from several previous 
reports suggesting distinct angiogenic and pro-inflammatory biological activities 
of lower molecular weight HA or HA oligomers. Lower molecular weight HA, but 
not high-molecular-weight HA, stimulates the production of metalloelastase and 
expression of inducible nitric oxide synthase in rat liver endothelial and Kupffer cells. 
In addition, it has been reported that low-molecular-weight degradation products of 
HA elicit pro-inflammatory responses by modulating the toll-like receptor-4 or by 
activating the nuclear factor kappa B (NF-kB). In contrast, high-molecular-weight 
HA manifests an anti-inflammatory effect via CD receptors and by inhibiting NF-kB 
activation [58] (Figure 6). During progression of inflammation and OS in the joints, 
HA depolymerizes into lower molecular weight compounds (2.7–4.5 MDa) which 
consequently diminish the mechanical and viscoelastic properties of the synovial 
fluid [51] as well as activate different signaling pathways. Randomized, double-
blinded, placebo-controlled trials have proven the effectiveness of HA (administered 
by the intra-articular injection or in the form of dietary supplements 48–240 mg/day) 
for the treatment of symptoms associated with synovitis [53].
Kogan et al. [59] suggest mechanisms, by which HA could exert its therapeutic 
effect: (i) restoration of elastic and viscous properties of the synovial fluid; (ii) 
induction of the endogenous synthesis of HA by synovial cells by the effect of 
exogenous HA, stimulation of chondrocyte proliferation, and inhibition of cartilage 
degradation; (iii) anti-inflammatory action of HA, since the therapy is associated 
with decreased inflammatory cell count in synovial fluid, modulation of cytokine 
expression, and reduction of ROS content; and (iv) analgesic effect. An important 
feature of HA is its antioxidant properties. The direct radical-scavenging proper-
ties of HA have been demonstrated in various experimental models. These results 
are in accord with the concept that hyaluronic acid mainly acts as a chemical ROS 
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and/or RNS scavenger in extracellular space [55]. In favor of a direct antiradical 
activity, there is also the ability of hyaluronic acid (biopolymer) to form a viscous, 
pericellular meshwork that restricts ROS movement in close proximity to cells and 
thus interferes with the oxidative cascade [55]. The presence of CD44 hyaluronate 
receptors on the plasma membrane of granulocytes, which mediate the internaliza-
tion of the biopolymer via endocytosis, offers another key to interpretation of the 
HA antioxidant mechanism of action, that is, the reduction in ROS and/or RNS is 
caused by hyaluronic acid internalization and the intracellular neutralization of the 
radicals [60]. One important pharmacological function of HA is the reduction of 
cellular superoxide generation and accumulation through nuclear factor erythroid 
2-related factor 2 (Nrf2) regulation, which is a master transcription factor in cellu-
lar redox reactions. Antioxidants and phase II detoxifying enzymes such as catalase 
(CAT), superoxide dismutase (SOD), heme oxygenase-1, glutathione S-transferase, 
glutathione peroxidase (GPx), and thioredoxin are coordinated at transcription 
level by Nrf2, so the hyaluronic acid could affect the activity and quantity of these 
antioxidant enzymes (Figure 7) [61].
The aim of this study was to compare the effect of different molecular weights of 
hyaluronic acid (0.43, 0.99, and 1.73 MDa) applied in two different doses (0.5 and 5 mg/
kg b.w.), on the rat hind paw volume and parameters of OS: activity of antioxidant 
enzymes in erythrocytes (SOD, GPx, CAT), total antioxidant capacity, and concentra-
tion of lipid hydroperoxides (LPx, marker of oxidative damage to lipids) in plasma.
3.2 Experimental design of adjuvant arthritis with administration of hyaluronan
Male Lewis rats were randomly divided into groups according to the treatment 
they received:
(1) Not treated control groups (HC)
(2) Arthritic animals not treated with HA (AA)
Figure 7. 
Hyaluronan increases enzymatic antioxidant defense through Nrf2 upregulation. HA, hyaluronan; AKT, serine/
threonine protein kinase; Nrf2, factor erythroid 2-related factor 2; CAT, catalase; SOD-1, superoxide dismutase-1; 
GPx-1, glutathione peroxidase; HO-1, hemeoxygenase-1; NQO-1, NAD(P)H (quinone)dehydrogenase 1.
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(3) Arthritic animals treated with hyaluronic acid (HA) during 28 days:
(a) Group NHA (Mw(HA) = 0.43 MDa, in an oral daily dose of  
0.5 mg/kg b.w.)
(b) Group 5NHA (Mw(HA) = 0.43 MDa, in an oral daily dose of 5 mg/kg b.w.)
(c) Group SHA (Mw(HA) = 0.99 MDa, in an oral daily dose of  
0.5 mg/kg b.w.)
(d) Group 5SHA (Mw(HA) = 0.99 MDa, in an oral daily dose of 5 mg/kg b.w.)
(e) Group VHA (Mw(HA) = 1.79 MDa, in an oral daily dose of 0.5 mg/kg b.w.)
(f) Group 5VHA (Mw(HA) = 1.79 MDa, in an oral daily dose of  
5 mg/kg b.w.).
Adjuvant arthritis was induced by a single intradermal injection of heat-inacti-
vated Mycobacterium butyricum [36, 37]. Blood was collected to obtain plasma and 
erythrocytes. Total antioxidant capacity and concentration of LPx were determined 
in plasma. Isolated erythrocytes were washed three times with 0.15 mol/l NaCl 
solution. After centrifugation (900 × g, 5 min, 4°C), erythrocytes were hemolyzed 
by adding a triple volume of cold distilled water and stored at −20°C until further 
analyses. Activities of Cu/Zn-superoxide dismutase (SOD), glutathione peroxidase 
(GPx) and catalase (CAT), and the concentration of hemoglobin (Hb) were deter-
mined in the hemolysate of erythrocytes. From clinical parameters hind paw volume 
(HPV) was evaluated [62]. The activity of SOD was determined using a commercial 
kit. The results are expressed in U of SOD per mg Hb. The activity of GPx was also 
determined by a commercial kit. The results are expressed in μkat per g Hb. CAT 
activity was determined by a modified method according to [63], and the results are 
expressed in μkat per g Hb. The total antioxidant capacity of plasma was measured 
using the Trolox equivalent antioxidant capacity (TEAC) assay [64]. Quantification 
was performed using the dose-response curve for the reference of antioxidant Trolox, 
a water-soluble form of vitamin E. The results are presented as mmol of Trolox per 
ml of plasma. The level of LPx in plasma was measured using the method previously 
described by [64], and the results are presented in nmol per ml of plasma. The experi-
mental data were expressed as the mean ± SEM. Statistical analysis was performed 
using Student’s t-test. The limit for statistical significance was set at p < 0.05.
3.3  Evaluation of results of administration of hyaluronans in experimental 
arthritis
The onset of AA confirmed the increased hind paw volume in arthritic groups 
(data not shown). HA administration did not cause a significant reduction of HPV 
in any molecular weight and at any doses used. Parameters of OS are summarized in 
Table 5. Rats with AA had significantly higher activity of SOD and CAT in erythro-
cytes as well as higher concentration of LPx in comparison to HC group. Activity of 
GPx was marginally increased (p = 0.054) and TEAC was not changed.
The effect of hyaluronic acid on antioxidant enzyme activities, the total anti-
oxidant capacity of plasma, and the effect on LPx concentration are summarized 
in Table 6. We have found significantly higher erythrocyte SOD activity after 
administration of HA in all molecular forms and doses, whereas GPx activity was 
significantly higher only after HA administration at the higher dose. At a lower 
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dose, we observed a significantly elevated GPx activity only in the SHA group 
(Mw(HA) = 0.99 MDa). For both enzymes, we have also noticed a significant dif-
ference between the effects of the same molecular forms of HA but administered at 
different doses. The higher HA dose (5 mg/kg b.w.) significantly increased the GPx 
activity compared to the lower dose (0.5 mg/kg b.w.).
Subanalysis based on the molecular weight of the administered HA revealed the 
higher SOD activity in the VHA group compared to NHA (p = 0.0013), in the 5SHA 
and 5VHA groups compared to 5NHA (p = 0.0025, respectively, p = 0.0308), and 
VHA compared to SHA (p = 0.0107). The higher GPx activity was found in SHA 
group in comparison to NHA (p = 0.0425), in 5SHA, respectively, 5VHA in com-
parison to 5NHA (p = 0.0217 respectively p = 0. 0058), and lower activity in VHA 
group in comparison to SHA (p = 0.0069). A similar trend was observed in the 
effect of HA on the total antioxidant capacity of plasma. The values of this param-
eter were increased in all groups but significantly only when HA was administered 
at a higher concentration.
Also, the higher HA dose significantly increased the total antioxidant capacity 
compared to the lower dose. Differences in the effect of HA with different molecu-
lar weights were seen only in the 5VHA group, whereas TEAC was significantly 
increased when compared to the 5NHA group (p = 0.0212). On the other hand, HA 
in all molecular weights and at both monitored doses significantly reduced CAT 
activity. The effect of different doses was found only in SHA and VHA groups, where 
the higher dose significantly reduced activity in SHA (p = 0.0004) and significantly 
increased activity in VHA (p = 0.0192). At higher doses, we found significant 
reductions of CAT activity in VHA compared to both NHA and SHA (p = 0.0018 and 
p = 0.0001) and in 5SHA compared to 5NHA (p = 0.0194). Concentration of LPx 
was significantly reduced in all monitored groups, with no differences in the effect 
of different molecular weights of HA or in the effect of doses.
Our study, for the first time, evaluated the ability of the HA to affect the activity 
of erythrocyte antioxidant enzymes, as well as total antioxidant capacity and LPx 
of rats with AA. We have found increased activities of antioxidant enzymes (SOD, 
GPx and CAT) in erythrocytes of AA rats with increased plasma LPx concentration. 
Administration of different molecular weights of HA (0.43, 0.99, and 1.73 MDa) 
applied in two different doses (0.5 and 5 mg/kg b.w.) resulted in a further increase in 
activities of these enzymes, but we observed a decreased concentration of plasma LPx.
Inflammatory diseases, including RA, are characterized by sustained overpro-
duction of ROS, accompanied by disruption of the antioxidant defense system 
resulting in local and systemic OS development in the affected joint-synovial fluid 
[65], and in addition to the joints, plasma and some organs are affected [66]. The 
results of the present work showed that in spite of the increased antioxidant enzyme 
Parameter HC AA P
SOD (U/mg Hb) 422.65 ± 15.93 546.48 ± 14.25 0.0001
GPx (μkat/g Hb) 51.10 ± 1.45 56.86 ± 2.26 0.054
CAT (μkat/g Hb) 2.61 ± 0.18 3.06 ± 0.09 0.044
TEAC (mmol/l) 4.01 ± 0.07 4.04 ± 0.09 n.s.
LPx (nmol/ml) 20.76 ± 3.55 53.34 ± 5.83 0.003
Control group (HC), arthritis group (AA), statistical significance (P).
Activities of superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT) in erythrocytes, total 
antioxidant capacity (TEAC), and concentration of lipoperoxides (LPx) in plasma were measured on the 28th day.
Table 5. 
Oxidative stress markers in rats with adjuvant arthritis.
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Parameter AA NHA 5NHA SHA 5SHA VHA 5VHA
SOD (U/mg Hb) 546.48 ± 14.25 615.26 ± 23.00* 817.37 ± 28.45*** 661.41 ± 24.34** 944.73 ± 41.35*** 777.17 ± 30.91*** 869.42 ± 34.96***
GPx (μkat/g Hb) 56.86 ± 2.26 55.53 ± 3.297 71.17 ± 3.76** 64.95 ± 2.65* 84.89 ± 4.20*** 55.44 ± 1.40 93.52 ± 6.83***
CAT (μkat/g Hb) 3.06 ± 0.09 2.61 ± 0.15* 2.40 ± 0.08*** 2.81 ± 0.12 2.06 ± 0.10*** 2.02 ± 0.05*** 2.28 ± 0.09***
TEAC (mmol/l) 4.04 ± 0.09 4.23 ± 0.09 4.57 ± 0.03** 4.07 ± 0.10 4.80 ± 0.24** 4.19 ± 0.10 4.73 ± 0.06**
LPx (nmol/ml) 53.34 ± 5.83 24.35 ± 1.19** 26.84 ± 1.70* 25.3 ± 4.67** 27.98 ± 3.45* 25.13 ± 5.53** 24.49 ± 2.67*
*p < 0.05.
**p < 0.01.
***p < 0.001 vs. AA.
NHA (Mw(HA) = 0.43 MDa, 0.5 mg/kg b.w.); 5NHA (Mw(HA) = 0.43 MDa, 5 mg/kg b.w.); SHA (Mw(HA) = 0.99 MDa, 0.5 mg/kg b.w.); 5SHA (Mw(HA) = 0.99 MDa, 5 mg/kg b.w.); VHA 
(Mw(HA) = 1.79 MDa, 0.5 mg/kg b.w.); 5VHA (Mw(HA) = 1.79 MDa, 5 mg/kg b.w.).
Activities of superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT) in erythrocytes, total antioxidant capacity (TEAC), and concentration of lipoperoxides (LPx) in plasma were 
measured on the 28th day.
Table 6. 
Effect of hyaluronic acid on oxidative stress markers.
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activities found in erythrocytes of rats with AA, lipid peroxidation in plasma is 
increased in comparison to control group. Lipid peroxides are generated at the site 
of tissue injury due to increased ROS production during chronic inflammation and 
diffuse into blood where they can be estimated [67]. Studies have reported raised 
levels of MDA, 4-hydroxynonenal, and other markers of oxidative lipid damage in 
the serum, plasma, and erythrocytes of RA patients [65, 68]. Kumar et al. [68] also 
found increased plasma SOD activity in patients with RA, similarly to Mazzetti 
et al. [69]. Similar results were found in early type 2 diabetes patients [70], where 
increased antioxidant defense in plasma and erythrocytes is explained as a potential 
mechanism that can overcome oxidative damage induced by ROS overproduction. 
There are some reports on erythrocyte SOD, CAT, and GPx activities in patients 
with RA or in rats with AA, but the results are controversial [71, 72]. It is possible 
that differences between different investigators’ results, regarding antioxidant 
status, are due to differences in the stage of the disease. Chronic inflammation may 
deplete antioxidant defenses, whereas acute inflammation can upgrade them [73].
In our study, we did not notice a change in total plasma antioxidant capacity in 
the group of arthritic rats, similarly to Bracht et al. [66] in the mono-arthritic rats. 
Vijayakumar et al. [74] confirmed susceptibility of erythrocytes to peroxide stress. 
They have found not only elevated plasma lipid peroxidation but also the excessive 
lipid peroxidation in erythrocytes and erythrocyte membranes. In addition, they 
found decreased glutathione levels and GPx activity in plasma but increase in eryth-
rocytes of RA patients as compared to healthy subjects. Superoxide radicals play an 
important role as a chemical mediator on the inflammatory response to RA. The 
increased activity of plasma SOD observed in the abovementioned studies as well as 
increased activity of SOD in erythrocytes observed in our study could therefore be 
found due to their function in dismutation of superoxide radicals excess. Thus, the 
activities of antioxidant enzymes in blood cells including erythrocytes could reflect 
the rate of OS in the affected cells. This could be a suitable approach for assessing 
the effect of therapy aimed to reduce inflammation and OS.
Our study demonstrated that HA (in all molecular weights and in both doses), 
orally administrated in a rat model of AA, affected all measured markers of 
OS. Furthermore, erythrocyte antioxidant markers including SOD and GPx, and 
total antioxidant capacity of plasma, increased significantly during 28 days of 
supplementation. On the other hand, we have found decreased erythrocyte CAT 
activity and plasma concentration of LPx. Based on our results, we cannot give a 
clear explanation how the HA can affect all observed parameters. Numerous studies 
have confirmed the effect of HA on the activity of these enzymes but in other cells 
and tissues and not in erythrocytes [75, 76]. It was confirmed that HA can reduce 
cellular superoxide generation and its accumulation through Nrf2 regulation which 
can induce transcription of antioxidant enzymes such as SOD, GPx, CAT, and oth-
ers [61]. Supplementary to its primary role in cytoprotection, Nrf2 is also linked to 
differentiation, proliferation, growth, and apoptosis, and it is thought that Nrf2 has 
evolved from an original role in hematopoiesis and the regulation of cell differentia-
tion from early lineages [77].
Based on this, we could assume that during proliferation and differentiation of 
hematopoietic stem cells, expression of antioxidant enzymes can be induced. In the 
induction of expression, the CD44 receptor, which binds HA and mediates its role 
as a signal molecule, could have importance. We could just speculate if the activities 
of antioxidant enzymes in erythrocytes reflect the effect of administered HA on the 
activities of these enzymes in other tissues as well. As we observed an increase in 
both SOD and GPx activities in erythrocytes of AA rats under HA supplementation, 
we anticipate a similar mechanism of HA action in other cells, e.g., in chondrocytes, 
where the increase in antioxidant potential could provide antioxidant protection 
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of synovial fluid and reduction of lipoperoxidation not only in the synovium but 
also in the plasma as what we have found in our study. Also, the direct antioxidant 
ability of HA, which has been described, could contribute to the reduction of 
lipoperoxidation [55]. However, further studies need to be made to confirm these 
assumptions.
4. Conclusion
New treatment strategies based on blockade of cytokine pathways in late stages 
of RA are progressing. In spite of their benefits, long-time utilization of these 
blocking agents has indicated side effects. The antioxidant defense system includes 
endogenous (enzymatic and nonenzymatic) and exogenous (dietary) antioxidants 
that interact in establishing redox homeostasis in the body. Therapeutic benefits 
from antioxidant treatment are primarily bound to reduction of systemic OS.
CoQ 10 treatment significantly improved concentrations of the investigated 
endogenous antioxidants (CoQ 9-total, CoQ 10-total, and gamma tocopherol in 
plasma). CoQ 10 for its bioenergetic, antioxidant, and anti-inflammatory properties 
might be therapeutically useful for a long-term supplementary administration to 
patients with inflammatory diseases such as RA.
In our study, we have shown the ability of per orally administered HA to improve 
the antioxidant defense (SOD, GPx, and total antioxidant capacity of plasma). 
This therapeutic effect of HA could be a result of direct (intestinal absorption) and 
indirect (intestinal cell immunomodulatory) anti-inflammatory activities. Recent 
results have shown that dietary high-molecular-weight HA can be distributed to 
connective tissues. Dietary HA could be beneficial for joints, knee pain, relief of 
synovial effusion, or inflammation and improvement of muscular knee strength. 
HA also binds to toll-like receptor-4 (TLR4) in the luminal surface of the large 
intestine resulting in the downregulation of systemic proinflammatory cytokines.
However, further research is needed with endogenous antioxidants, mainly 
human studies, in order to establish an antioxidative treatment approach in inflam-
matory-based diseases such as RA.
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